Abstract 845: Do Statins Increase Incidence of Diabetes Mellitus? A Meta-analysis of Randomized Clinical Trials
Background: Statins reduce mortality and morbidity in patients at risk or with documented coronary artery disease and thus are widely prescribed. Report from randomized trials (RCT) suggested that statins might be protective or even increase the incidence of diabetes mellitus (DM). The increase in DM may be related to the use of lipophilic statins.
Aim: To evaluate the use of statins and incident diabetes mellitus in randomized clinical trials (RCT) and pre-specify an analysis including lipophilic statins only.
Methods: An electronic search of the literature using MEDLINE with the following keywords: statins, diabetes mellitus, HMG CoA reductase inhibitors, incident diabetes. The selection criteria for the meta-analysis were:
randomized, placebo-controlled clinical trials,
follow up more than 1 year,
use of statin for primary or secondary prevention of cardiovascular disease,
data on incident DM. Two independent extractors retrieved data and disagreements were solved by consensus. RevMan version 4.2.9 was used for data analysis, and I2 test to quantify heterogeneity. Fixed or random effects model was applied as appropriate.
Conclusion: Our meta-analysis revealed that overall, the use of statins are not significantly associated with the development of DM, however the use of lipophilic statins (simvastatin, atorvastatin) revealed a borderline statistically significant increase in the diagnosis of DM.